Browse studies

Find your next paid study

179 recruiting studies matching your filters

Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer

This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have rece…

Endometrial Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT04774419

Phase 1

A Phase 1/2, Open-label Clinical Trial to Evaluate Safety and Efficacy of Combination Paclitaxel and BMX-001, in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripher…

Ovarian NeoplasmsEndometrial Cancer, Endometrial Neoplasm

Estimated

~$150 – $4,200

Actual pay is set by the research site.

BioMimetix JV, LLCNCT06620029

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options …

LevonorgestrelIntrauterine SystemsPrevention+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07382583

Phase 1

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety a…

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Bio-Path Holdings, Inc.NCT04196257

Phase 2

RESOLVE: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin and Gedatolisib

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs…

Endometrial Cancer

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT03675893

Phase 1

Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part…

Endometrial CancerMetastasisEndometrioid Endometrial Cancer+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

UNC Lineberger Comprehensive Cancer CenterNCT05542407

Phase 2

Evaluating Promising Progestins in Endometrial Cancer Through a Rotating Umbrella Surgical Window Trial - The PRO-WINDOW TRIAL for Endometrial Cancer

This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and pre…

Endometrial Endometrioid AdenocarcinomaEndometrial Hyperplasia

Estimated

~$75 – $3,000

Actual pay is set by the research site.

New Mexico Cancer Research AllianceNCT07436793

Phase 1

Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors

Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metasta…

Non-small Cell Lung CancerColorectal CarcinomaPancreatic Ductal Adenocarcinoma+3 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AstraZenecaNCT06218914

Phase 1

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

Advanced Solid TumorOvarian CancerEndometrial Cancer+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

TORL Biotherapeutics, LLCNCT05103683

Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel an…

Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube Carcinoma+71 more

Phase 2

Adjuvant Proton Whole Pelvis Radiation Therapy for Treatment of Post-Surgical Gynecologic Cancers

This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-sur…

Cervical CancerUterine CancerEndometrial Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT05758688

Phase 1

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Imaging of Patients With Endometrial Cancer Planned for Surgery

The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the…

Endometrial CancerNear Infrared Fluorescence ImagingCYTALUX (Pafolacianine) Injection+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT07278986